Abstracts Archive - Page 2553 of 2607 - ACR Meeting Abstracts

Abstract Number: 766 • 2012 ACR/ARHP Annual Meeting
Anemia May Provide Clinically Relevant Information Beyond Conventional Disease Activity Assessment to Predict Radiographic Damage Progression in Rheumatoid Arthritis
Burkhard Moller¹, Frauke Förger², Peter M. Villiger³ and Axel Finckh⁴, ¹Rheumatology, Inselspital University Hospital, Bern, Switzerland, ²Rheumatology, Clinical Immunology and Allergology, Inselspital University Hospital of Bern, Bern, Switzerland, ³Rheumatology, Immunology and Allergology, University Hospital Bern, Bern, Switzerland, ⁴Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Anemia may provide clinically relevant information beyond conventional disease activity assessment to predict radiographic damage progression in Rheumatoid ArthritisBurkhard Möller, Frauke Förger, Peter M. Villiger,…
Abstract Number: 767 • 2012 ACR/ARHP Annual Meeting
Patients with Early Inflammatory Arthritis Who Fulfil the 2010 American College Rheumatology/European League Against Rheumatism Classification Criteria for Rheumatoid Arthritis Have Increased Mortality Compared to Those Who Do Not: Results From the Norfolk Arthritis Register
Jh Humphreys¹, Suzanne Verstappen², Mark Lunt³, Jackie Chipping⁴, Kimme Hyrich⁵, Tarnya Marshall⁶ and Deborah Symmons⁷, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ²Arthritis Research UK Epidemiology Unit,, University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, ³Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁴Norfolk Arthritis Register, School of Medicine Health Policy and Practice Faculty of Health UEA, Norwich, United Kingdom, ⁵Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁶Rheumatology, Norfolk and Norwich University Hospitals Trust, Norwich, United Kingdom, ⁷Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester Academy of Health Sciences, Manchester, United Kingdom
Background/Purpose: Mortality is increased in rheumatoid arthritis (RA) in comparison with the general population. The majority of studies have used the 1987 ACR criteria to…
Abstract Number: 768 • 2012 ACR/ARHP Annual Meeting
An Easy to Use Referral Model for Arthritis From the Rotterdam Early Arthitis Cohort
C. Alves¹, Jolanda J. Luime¹, Darian P. Shackleton², P.J. Barendregt³, A.H. Gerards⁴ and Johanna M.W. Hazes¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Medisch Centrum Parklaan, Netherlands, ³Department of Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ⁴Department of Rheumatology, Vlietland Hospital, Schiedam, Netherlands
Background/Purpose: The first hurdle general practitioners (GPs) face to identify Rheumatoid Arthritis(RA) is to recognize presence of arthritis. Due to the low incidence of arthritis…
Abstract Number: 769 • 2012 ACR/ARHP Annual Meeting
2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria Predicts Radiogical, but Not Clinical Outcomes At 18 Months Into Disease in a Canadian Early Arthritis Cohort
Ariel Masetto¹, Arthur J. Fernandes², Patrick Liang³, Pierre Cossette⁴ and Gilles Boire⁵, ¹Rheumatology, CHUS, Fleurimont, QC, Canada, ²Rheumatology Division, Universite de Sherbrooke, Sherbrooke N, Canada, ³Rheumatology Division, CHUS, Sherbrooke, QC, Canada, ⁴Internal Medicine Departement, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada
Background/Purpose: The potential of the 2010 ACR/EULAR rheumatoid arthritis (RA) classification criteria to discriminate early arthritis patients according to their clinical and radiological outcomes needs…
Abstract Number: 770 • 2012 ACR/ARHP Annual Meeting
Is Late Onset Rheumatoid Arthritis (LORA) Really a Distinct Entity of RA? Results From the Swiss Observational Cohort
Ruediger Mueller¹, Toni Kaegi¹, Axel Finckh² and Johannes von Kempis¹, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Rheumatology, Geneva University Hospitals, Geneva 14, Switzerland
Background/Purpose: Rheumatoid arthritis (RA) is generally described as a disease with two peaks of onset, either late (late onset RA, LORA) or early (young onset…
Abstract Number: 771 • 2012 ACR/ARHP Annual Meeting
Discontinuation of Adalimumab without Functional and Radiographic Damage Progression After Achieving Sustained Remission in Patients with Rheumatoid Arthritis (the HONOR study): 1-Year Results
Yoshiya Tanaka¹, Shintaro Hirata¹, Shunsuke Fukuyo¹, Masao Nawata², Satoshi Kubo², Kunihiro Yamaoka² and Kazuyoshi Saito¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: Discontinuing anti-TNF therapy after achieving a stable low disease activity (LDA) or remission (REM) state in rheumatoid arthritis (RA) has become an important area…
Abstract Number: 772 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study
Arthur Kavanaugh¹, Paul Emery², Ronald F. van Vollenhoven³, Ara H. Dikranian⁴, Rieke Alten⁵, Micki Klearman⁶, David Musselman⁷, Sunil Agarwal⁷, Jennifer Green⁸ and Cem Gabay⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Karolinska Institute, Stockholm, Sweden, ⁴San Diego Arthritis Medical Clinic, San Diego, CA, ⁵Teaching Hospital of the Charité, University of Berlin, Berlin, Germany, ⁶Roche, South San Francisco, CA, ⁷Genentech Inc, South San Francisco, CA, ⁸Roche, Welwyn Garden City, United Kingdom, ⁹Rheumatology, Geneva University Hospitals, Geneva, Switzerland
Background/Purpose: Approximately one-third of RA pts treated with biologics receive them as monotherapy (ie, without other DMARDs).1-3 Although tocilizumab (TCZ), an IL-6 receptor inhibitor, has…
Abstract Number: 733 • 2012 ACR/ARHP Annual Meeting
Intra-Articular Injection of Adipose-Derived Stem Cells Inhibits Activation of the Synovium and Protects Against Cartilage Damage and Enthesophyte Formation in Murine Experimental Osteoarthritis
Peter L.E.M. van Lent¹, Menno C. ter Huurne², Arjen B. Blom³, Rik Schelbergen³, Louis Casteilla⁴, Thomas Vogl⁵, Johannes Roth⁵, Roxane Blattes⁴, Christian Jorgensen⁶ and Wim B. van den Berg⁷, ¹Rheumatology Research & Advanced Therpeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴STROMALab UPS/CNRS UMR5273, INSERM U1031, Toulouse, France, ⁵Institute of Immunology, University of Muenster, Munster, Germany, ⁶Department of therapy & Immuno-Rhumatology, Hospital Lapeyronie, Montpellier, France, ⁷Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: OA lesions are treated with mesenchymal stem cells aiming to enhance tissue repair by transformation to eg. chondrocytes. Recently it has been shown that…
Abstract Number: 734 • 2012 ACR/ARHP Annual Meeting
Chemokine (C-C Motif) Receptor 2 Signaling Mediates Persistent Pain in Experimental Osteoarthritis
Rachel E. Miller¹, Phuong Tran², Rosalina Das², Nayereh Ghoreishi-Haack², Richard J. Miller³ and Anne-Marie Malfait⁴, ¹Rheumatology/Biochemistry, Rush University Medical Center, Chicago, IL, ²Rheumatology, Rush University Medical Center, Chicago, IL, ³Molecular Biochemistry and Pharmacology, Northwestern University, Chicago, IL, ⁴Internal Medicine/Biochemistry, Rush University Medical Center, Chicago, IL
Background/Purpose: To investigate the role of MCP-1/CCR2 in the development of pain in osteoarthritis (OA) using a mouse model, destabilization of the medial meniscus (DMM).…
Abstract Number: 735 • 2012 ACR/ARHP Annual Meeting
Mass Spectrometry Assays of Plasma Biomarkers to Predict Radiographic Progression of Knee Osteoarthritis
Susan Y. Ritter¹, William M. Reichmann², Jamie E. Collins³, Alejandra Garces⁴, Bryan Krastins⁴, David Sarracino⁴, Mary Lopez⁴, Elena Losina³ and Antonios O. Aliprantis⁵, ¹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Orthopedics, Brigham and Women's Hospital, Boston, MA, ³Orthopaedic and Arthritis Center for Outcomes Research, Brigham and Women's Hospital, Boston, MA, ⁴Thermo Fisher Scientific BRIMS Center, Cambridge, MA, ⁵Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Biomarkers to identify osteoarthritis (OA) patients at risk for disease progression are needed. Recently, we performed a proteomic analysis of knee synovial fluid from…
Abstract Number: 736 • 2012 ACR/ARHP Annual Meeting
Inhibition of Interleukin-17 Signaling Via De-Ubiquitinatio
Sarah L. Gaffen¹ and Abhishek Garg², ¹Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology/Clinical Immun, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: IL-17A (IL-17) is a proinflammatory cytokine that contributes to the pathogenesis of various autoimmune diseases, including rheumatoid arthritis (RA), multiple sclerosis (MS) and psoriasis.…
Abstract Number: 737 • 2012 ACR/ARHP Annual Meeting
Citrullination of ENA-78/CXCL5 Results in Conversion From a Non-Monocyte Recruiting to a Monocyte Recruiting Chemokine
Ken Yoshida¹, Olex Korchynskyi², Paul P. Tak³, Takeo Isozaki⁴, Jeffrey H. Ruth⁵, Phillip Campbell⁶, Dominique L. Baeten⁷, Danielle M. Gerlag⁷, M. Asif Amin⁸ and Alisa E. Koch⁹, ¹Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ²Department of Cellular Proliferation and Apoptosis, Institute of Cell Biology, Lviv, Ukraine, ³Departments of Experimental Immunology and Internal Medicine, GlaxoSmithKline U.K. and Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁴Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁵Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ⁶Department of Internal Medicine, University of Michigan, Ann Arbor, MI, ⁷Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁸Department of Medicine, University of Michigan, Ann Arbor, MI, ⁹Internal Medicine - Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Citrullination is a post-translational modification that is the conversion of arginine to citrulline in proteins mediated by peptidylarginine deiminase (PAD). Antibodies directed towards the…
Abstract Number: 738 • 2012 ACR/ARHP Annual Meeting
A Novel Orally Active Phosphatidylinositol 3-Phosphate 5-Kinase (PIKfyve) Inhibitor Ameliorates Mouse Psoriasis-Like Model by Inhibition of Interleukin-12 and Interleukin-23 Production From Macrophages
Ayatoshi Andou, Eviryanti Agung, Yukie Seki, Yoichiro Shima, Sen Takeshita, Takashi Yamamoto and Hiroyuki Eda, Exploratory Research Laboratories, Ajinomoto Pharmaceuticals Co., Ltd., Kanagawa, Japan
Background/Purpose: Phosphatidylinositol (3,5)-bisphosphate (PI(3,5)P2) is the most recently-identified phospholipid component of cellular membrane. Phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) is a critical enzyme for the synthesis of…
Abstract Number: 739 • 2012 ACR/ARHP Annual Meeting
The Serine Arginine Protein SF2/ASF Is a Novel Regulator of IL-2 Transcription and Restores IL-2 Production in T Lymphocytes From SLE Patients
Vaishali R. Moulton¹, Alexandros P. Grammatikos¹ and George C. Tsokos², ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease which afflicts mainly women in the reproductive years, and causes painful arthritis, skin disease and…
Abstract Number: 740 • 2012 ACR/ARHP Annual Meeting
Select Soluble Inflammatory Mediators Are Detected Prior to and Increase At Systemic Lupus Erythematosus Classification
Melissa E. Munroe¹, Jourdan R. Anderson², Julie M. Robertson³, Timothy B. Niewold⁴, George C. Tsokos⁵, Michael P. Keith⁶, John B. Harley⁷ and Judith A. James⁸, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Section of Rheumatology and Gwen Knapp Center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ⁵Medicine/Rheumatology, BIDMC, Harvard Medical School, Boston, MA, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD, ⁷Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁸Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation; Oklahoma University Health Sciences Center, Oklahoma City, OK
Background/Purpose: The processes that lead to clinical illness in systemic lupus erythematosus (SLE) years before diagnosis are not well characterized. Several cytokines have been associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].